Genetic and Genomic Testing: UltaGenomics DNA Insights, Hereditary Risk, and Pharmacogenomics

Genetic and genomic testing can answer focused questions about inherited conditions, carrier status, medication response, and broader DNA patterns. The value of a result depends on choosing the right method, understanding exactly what was analyzed, and interpreting the finding with personal and family history.

Key takeaways

• Genetic testing usually examines a gene, variant, chromosome, or focused panel. Genomic testing examines a broader portion of DNA and may create more uncertain or secondary findings.
• A DNA result is not a diagnosis by itself. Its meaning depends on test scope, evidence quality, medical and family history, ancestry representation, and whether a finding has been confirmed when needed.
• A negative result does not always eliminate risk. The test may not cover every relevant gene, variant type, or condition.
• A variant of uncertain significance should not be treated as a disease-causing result or used alone for irreversible medical decisions.
• Pharmacogenomic information may inform medication selection or dosing for some gene-drug pairs, but it is only one part of prescribing.
• Genomic data can affect relatives and may have privacy or insurance implications. Review consent, data use, retention, and deletion policies before ordering.

What can genetic and genomic testing tell you?

Genetic and genomic testing can identify inherited variants, carrier status, selected disease-risk signals, and DNA differences that may influence response to certain medicines. It can also produce negative, uncertain, or secondary findings. A useful result must answer a defined question, come from an appropriate method, and be interpreted with clinical and family context. Testing cannot predict every future illness, explain every symptom, or guarantee that a medicine will work. Before ordering, confirm the genes and variant types covered, the laboratory and interpretation process, whether confirmation or counseling may be needed, and how your sample and data will be handled.

The language of genetics and genomics

The terms are related but not interchangeable. Understanding them prevents a broad wellness report from being mistaken for a diagnostic evaluation.

Term	Practical meaning	Important limit
Genetic testing	Usually evaluates a specific gene, variant, chromosome, or focused group of genes.	A focused assay may miss changes outside its defined scope.
Genomic testing	Evaluates a broader set of DNA, sometimes including many genes, the protein-coding exome, or most of the genome.	More data can mean more uncertain and secondary findings, not automatically more useful answers.
Germline variant	An inherited or egg-or-sperm-origin change that is generally present throughout the body and may be shared with relatives.	Not every germline variant affects health.
Somatic variant	An acquired change found in particular cells, such as tumor cells.	Tumor profiling does not replace an evaluation for inherited risk.
Epigenetics	Changes in how genes are regulated without changing the underlying DNA sequence.	Many consumer-facing epigenetic measures are still being evaluated for clinical utility.
Current biomarker	A present-day measurement in blood or another specimen that reflects physiology now.	It is not the same as inherited DNA and may change over time.

For a broader orientation to specimens, reference intervals, and routine laboratory terminology, see the complete guide to lab tests and blood work.

UltaGenomics and currently available options

Ulta Lab Tests currently maintains a Genetic Testing category organized around health and wellness themes. On August 7, 2026, the category structure was live, but individual UltaGenomics products within those newer thematic subcategories were not consistently available for direct verification. This article therefore does not invent product names, coverage, reports, turnaround times, or clinical claims for that catalog.

Separate, directly verified options for selected inherited-condition questions are listed below. Availability, eligibility, specimen requirements, preparation, and product details can change. Open the linked product page immediately before ordering and review the current information in full.

Directly verified inherited-condition and related options

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
BRCAvantage Ashkenazi Jewish Screen Category: focused inherited-cancer screen Status: direct product page verified	Looks for a limited set of founder variants associated with hereditary breast and ovarian cancer risk in people with relevant Ashkenazi Jewish ancestry. It is used for a narrow ancestry- and history-dependent question.	Blood specimen; no preparation was displayed on the verified product page. This is not a comprehensive hereditary-cancer evaluation, and a negative result does not exclude other BRCA1, BRCA2, or cancer-risk variants.
Cystic Fibrosis Expanded Screen - CFvantage Category: carrier or inherited-condition screening Status: direct product page verified	Evaluates a defined set of CFTR variants associated with cystic fibrosis and is used for carrier or inherited-condition screening in the appropriate context.	Blood specimen; no preparation was displayed on the verified product page. Scope matters: a negative result reduces but does not eliminate carrier or disease risk. Review the current coverage and residual-risk discussion.
CFTR Intron 8 Poly-T Analysis Category: targeted variant analysis Status: direct product page verified	Examines a specific CFTR region that can modify the clinical effect of certain CFTR findings and may support interpretation of other CFTR results.	Blood specimen; no preparation was displayed on the verified product page. It is a targeted analysis, not a complete CFTR sequence or a stand-alone explanation for symptoms.
Gaucher Disease, DNA Mutation Analysis Category: inherited-condition analysis Status: direct product page verified	Evaluates defined DNA changes associated with Gaucher disease and may support a focused inherited-condition question.	Confirm the current specimen and preparation requirements on the product page. Clinical findings, ancestry, family history, and assay coverage determine whether this is the right scope; a broader genetics evaluation may be needed.
Hereditary Hemochromatosis DNA Mutation Analysis Category: inherited iron-overload risk Status: direct product page verified	Looks for selected inherited variants associated with hereditary hemochromatosis and may support evaluation of inherited iron-overload risk.	Blood specimen; no preparation was displayed on the verified product page. Genotype does not by itself establish iron overload or organ injury. Current iron markers and clinical evaluation provide essential context.
Factor V Leiden Mutation Analysis Category: inherited thrombophilia Status: direct product page verified	Looks for the Factor V Leiden variant associated with increased venous-thrombosis susceptibility and may support a targeted inherited-thrombophilia evaluation.	Blood specimen; no preparation was displayed on the verified product page. It does not predict whether or when a clot will occur. Testing is not routine population screening and should be matched to history and professional guidance.
Prothrombin (Factor II) 20210G>A Mutation Analysis Category: inherited thrombophilia Status: direct product page verified	Looks for a specific prothrombin-gene variant associated with increased venous-thrombosis susceptibility and may support a targeted inherited-thrombophilia evaluation.	Blood specimen; no preparation was displayed on the verified product page. It does not measure a current clot or determine treatment by itself. Use should be guided by personal, pregnancy, medication, and family history.
Sickle Cell Trait Screening Panel Category: inherited hemoglobin condition screen Status: direct product page verified	Uses hematology and hemoglobin methods to screen for sickle cell trait and related hemoglobin patterns; it is not a DNA-sequencing product.	Blood specimen; no preparation was displayed on the verified product page. Recent transfusion and other factors can affect interpretation, and an abnormal or unclear pattern may require confirmatory or molecular evaluation.

Selection safeguard: The list above is educational and not a recommendation that every person order every option. A focused product may be inappropriate when the real question requires a broader panel, deletion-and-duplication analysis, sequencing, family-based testing, or a clinician-directed diagnostic workup.

Where different testing roles fit

Testing role	Appropriate use	Boundary
Common or first-line	History, family history, counseling, and the narrowest adequate method usually come before choosing a product.	There is no universal first-line DNA product for every adult.
Risk-based or targeted	Focused inherited-cancer, carrier, iron-risk, or thrombophilia analysis when ancestry, history, a relative's report, or a clinical question supports it.	A targeted assay may miss other relevant genes or variant types.
Monitoring	Current biomarkers may be trended when a clinician is monitoring physiology, medication effects, or disease.	Germline DNA is generally not repeated for serial monitoring.
Specialist-directed	Broad sequencing, pediatric evaluation, prenatal diagnosis, predictive neurologic testing, and complex hereditary-cancer assessment.	These questions often require consent, phenotype review, counseling, and a plan for secondary findings.
Emerging or insufficiently validated	Some polygenic, wellness, and epigenetic reports may be useful for education or research.	Do not treat an emerging score as a diagnosis or validated treatment target.
Generally not appropriate for broad routine screening	High-impact predictive testing, inherited-thrombophilia analysis, and limited founder-variant screens without a relevant question.	Over-testing can create uncertain findings, false reassurance, anxiety, and unnecessary follow-up.

Start with the question

The best first step is not choosing the largest panel. It is writing a one-sentence question that a result could realistically answer.

Educational framework—not a diagnostic or treatment algorithm.

1. Define the decision. Are you investigating a personal diagnosis, an inherited family risk, reproductive carrier status, medication response, or exploratory wellness information?
2. Record the evidence. Note diagnoses, age at onset, ancestry when relevant, pregnancy plans, medication history, and a three-generation family history if possible.
3. Choose the narrowest adequate scope. A known familial variant may need targeted testing; unexplained overlapping symptoms may require a panel or broader clinician-directed evaluation.
4. Ask what happens after each possible result. Plan for positive, negative, uncertain, and secondary findings before testing.
5. Decide whether counseling is needed before ordering. Pretest counseling is especially valuable for hereditary cancer, neurologic disease, pediatric testing, reproductive decisions, and broad sequencing.

Question	Often-considered approach	Key check before ordering
A relative has a documented pathogenic variant	Targeted familial-variant analysis	Obtain the relative's report and confirm the exact gene, variant, and laboratory nomenclature.
A family pattern suggests one of several syndromes	Clinician-selected multigene panel	Confirm genes, variant types, deletion-and-duplication coverage, and the plan for uncertain findings.
A couple is assessing reproductive carrier risk	Condition-specific or expanded carrier screening	Review professional guidance, ancestry limitations, residual risk, partner testing, and timing.
A medication has a recognized gene-drug relationship	Focused pharmacogenomic analysis	Confirm that the result has an applicable prescribing guideline or label and that the prescriber will review it.
The goal is broad wellness exploration	Consumer or wellness genomics, if chosen after informed consent	Separate educational associations from validated clinical findings and plan confirmation before medical action.

Clarify the role of the result

Role	Purpose	Do not confuse it with
Screening	Looks for risk or a possible finding before a diagnosis is established.	A definitive diagnosis.
Risk assessment	Combines DNA, history, and other factors to estimate susceptibility.	Certainty that disease will or will not occur.
Diagnostic support	Helps evaluate a person with signs, symptoms, or a strong clinical suspicion.	A stand-alone explanation that ignores phenotype and other causes.
Confirmation	Verifies a high-impact or preliminary finding using an appropriate specimen and method.	Repeating the same weak signal without a confirmation plan.
Baseline assessment	Records current biomarkers before an intervention or treatment when clinically appropriate.	Inherited DNA risk.
Medication monitoring	Tracks present physiology, safety, or effectiveness during treatment.	A pharmacogenomic result, which does not replace ongoing monitoring.
Disease monitoring	Follows a diagnosed condition with validated current measures.	Population screening or prognosis.
Prognosis	Estimates possible future course using condition-specific evidence.	A guarantee of severity or timing.
Acute or emergency use	Requires immediate clinical evaluation and validated urgent diagnostics.	Waiting for a consumer genetic or routine laboratory report.

Methods and scopes

A product name alone does not reveal what a laboratory can detect. Ask for the analytical method, reportable range, genes or regions covered, and important exclusions.

Method or scope	Typical strength	What it may miss or complicate
Targeted variant analysis	Efficient when a specific familial or population-associated variant is the question.	Other variants in the same gene and other genes.
Single-gene sequencing	Detailed assessment when one gene strongly fits the presentation.	Some copy-number changes, repeat expansions, structural changes, or difficult regions unless explicitly covered.
Multigene panel	Evaluates several genes that can cause overlapping conditions.	More uncertain findings; panels differ substantially in genes and methods.
Chromosomal microarray	Detects many missing or extra DNA segments across the genome.	Usually does not detect most single-letter variants or balanced rearrangements.
Exome sequencing	Surveys most protein-coding regions and can help with genetically heterogeneous presentations.	Noncoding regions, some structural variants, repeat expansions, mitochondrial changes, and low-coverage regions.
Genome sequencing	Provides broad sequence coverage and may detect a wider range of changes, depending on the platform.	Interpretation remains incomplete; some technically difficult changes still need specialized methods.
Genotyping array	Efficiently checks many predefined common variants.	Rare or unlisted variants and many structural changes; clinically important findings may require confirmation.

Individual test versus panel: Use a focused approach when the causal variant or gene is well established. Consider a panel when several genes plausibly explain the same clinical picture. Broader testing is not inherently better: it increases the chance of uncertain and unrelated findings.

Aliases matter: A condition, gene, protein, and historical syndrome may have different names. Confirm that the ordered assay matches the gene and variant type on the family report or clinician's order rather than relying on a familiar condition name alone.

Evidence, validity, and clinical utility

Three different questions determine whether a test is trustworthy and useful:

1. Analytical validity: Does the laboratory accurately detect the change it claims to measure?
2. Clinical validity: How strongly and consistently is that change associated with a disease, trait, or drug response?
3. Clinical utility: Will the result meaningfully improve a healthcare decision or outcome for this person?

A test can be analytically accurate yet have limited clinical utility. This distinction is especially important for low-effect common variants, polygenic scores, broad wellness traits, and emerging epigenetic measures. Evidence may not generalize equally across ancestry groups when discovery or validation datasets are not representative.

Questions to ask about evidence

• Was the association replicated in independent populations?
• What is the effect size, penetrance, or residual risk, and how uncertain is it?
• Does the report distinguish pathogenic, likely pathogenic, uncertain, likely benign, and benign classifications?
• Is the classification current, and does the laboratory offer a reanalysis or amended-report policy?
• Would a different method be required to confirm a result before medical action?
• Is there a professional guideline connecting the finding to a specific clinical decision?

Laboratory regulation and test evidence are related but not identical. CLIA establishes federal quality standards for laboratories that test human specimens, while clinical validity and utility require separate evaluation of the evidence for the intended use.

How to interpret genetic and genomic results

Read the laboratory's exact wording, not a simplified color or risk label. The same result can have different implications depending on why testing was performed.

Result	What it may mean	What it does not mean
Pathogenic or likely pathogenic	Evidence supports a disease association, carrier state, or actionable gene-drug relationship within the report's scope.	It does not automatically predict severity, age of onset, or certainty that disease will occur.
Negative	No reportable finding was detected within the tested regions and methods.	It does not exclude every genetic cause or return risk to zero.
Variant of uncertain significance	Available evidence cannot determine whether the variant contributes to disease.	It is not a positive result and should not drive irreversible management by itself.
Carrier finding	A person carries a variant associated with a recessive or X-linked condition.	It does not always mean the carrier has the condition; reproductive and personal-health implications vary.
Secondary finding	A medically relevant result unrelated to the original reason for broad sequencing.	It is not the same as an incidental raw-data association, and policies differ by laboratory and test.
Polygenic risk score	A statistical estimate combining many common variants.	It is not a diagnosis, may not transfer well across populations, and does not include every genetic or environmental contributor.

Reference intervals and decision thresholds

Many inherited DNA reports use categorical classifications rather than routine numerical reference intervals. A classification is an evidence judgment, not a laboratory value that becomes more dangerous simply because it is farther from a cutoff. Current biomarkers may use reference intervals or clinical decision thresholds, and those concepts should not be imported into DNA interpretation without explanation.

For practical guidance on routine reports, flags, ranges, and trends, review how to read and understand lab results.

When to confirm or reinterpret a result

False-positive and false-negative findings are possible because of specimen problems, technical limits, mosaicism, data-processing errors, or interpretation limits. The chance and consequences vary by method and intended use. Confirmation is most important when a result is unexpected, conflicts with the clinical picture, or could trigger an irreversible decision.

• Confirm medically important consumer or research findings in a qualified clinical laboratory before changing care.
• Ask whether a positive finding requires a second specimen or an orthogonal method.
• Revisit an uncertain result periodically because evidence and classifications can change.
• Share the original report, not a screenshot or paraphrase, with the interpreting professional.
• When possible, test an affected relative first if that strategy is more informative for the family.

Pharmacogenomic testing

Pharmacogenomics examines how inherited DNA differences may influence the effectiveness, exposure, or adverse-effect risk of certain medicines. It can be useful when a specific gene-drug relationship is supported by a prescribing guideline or drug label and the result will be reviewed by the prescriber.

On August 7, 2026, the Ulta Lab Tests Pharmacogenetic Lab Tests category was live but displayed no directly orderable products. No individual pharmacogenomic product is named or linked here until an exact product page can be verified.

What pharmacogenomics can and cannot do

• It may help interpret a recognized gene-drug pair; it does not predict every cause of benefit, nonresponse, or adverse effects.
• It may inform selection or dosing for some medicines; it does not replace diagnosis, kidney and liver assessment, drug-interaction review, age, pregnancy status, adherence, or clinical monitoring.
• A result may remain relevant over time because germline DNA usually does not change, but prescribing guidance and evidence can change.
• Different laboratories may analyze different genes, alleles, copy-number changes, or phenotype-translation rules. Compare scope before assuming reports are equivalent.

Medication warning: Never start, stop, substitute, or change the dose of a prescription medicine based only on a pharmacogenomic report. Review the result with the prescribing clinician or pharmacist. The FDA's pharmacogenetic association table is not a recommendation that everyone be tested before receiving a listed medication, and CPIC guidance is designed to help use results that are already available rather than decide whether testing should be ordered.

DNA plus current laboratory context

DNA can describe inherited susceptibility, while current biomarkers show what may be happening physiologically now. They answer different questions. Pairing them can be informative only when the combination is relevant to a defined health question.

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
A1c Test Category: current metabolic context Status: direct product page verified	Estimates average blood-glucose exposure over roughly the prior two to three months and is used as current glycemic context.	Blood specimen; no preparation was displayed on the verified product page. Conditions that alter red-blood-cell lifespan can affect interpretation. It does not measure inherited genetic risk.
Ferritin Test Category: current iron context Status: direct product page verified	Measures ferritin, a protein used to assess stored iron, and helps evaluate current iron status alongside an inherited iron-risk question.	Blood specimen; no preparation was displayed on the verified product page. Inflammation and other conditions can influence ferritin, so it should not be interpreted alone.
Iron and Total Iron-Binding Capacity Test Category: current iron context Status: direct product page verified	Measures circulating iron and iron-binding capacity used to calculate or interpret iron saturation and adds current physiology to an inherited iron-overload question.	Blood specimen. Preparation, timing, diet, supplements, and illness can influence iron measures; follow the current product-page instructions.
Comprehensive Metabolic Panel Test (CMP) Category: current metabolic and organ-function context Status: direct product page verified	Measures a group of current chemistry markers related to glucose regulation, electrolytes, proteins, and liver and kidney context.	Blood specimen; follow the current product-page preparation instructions. Hydration, food intake, medicines, illness, and collection timing can influence some components. It cannot confirm or refute most inherited variants.

Do not create a broad bundle merely because two products are available. A healthcare professional can help determine whether a current biomarker changes the interpretation or management of a particular genetic finding.

Preparation, collection, and factors that can affect results

DNA itself is generally stable, but specimen quality, identity, collection technique, recent transfusion, transplant history, active blood cancer, mosaicism, and laboratory method can affect what a result represents. Preparation for a paired current biomarker may be different from preparation for DNA analysis.

Current biomarkers also have biological and analytical variation. Food intake, hydration, time of day, exercise, acute illness, menstrual or pregnancy status, medicines, supplements, specimen handling, and assay method can affect some results. Compare trends only when the measure, units, clinical context, and collection conditions are sufficiently comparable.

1. Open the exact linked product page on the day you order and follow its current specimen and preparation instructions.
2. Confirm whether the specimen is blood, saliva, cheek swab, or another material and whether a collection kit is required.
3. Tell the interpreting professional about bone-marrow or solid-organ transplant, recent transfusion, active hematologic malignancy, or a suspected mosaic condition.
4. Do not stop medication or supplements unless the prescribing or treating professional instructs you to do so.
5. Use the same legal identity and date of birth across the order, specimen, and clinical record to reduce matching errors.
6. Keep a copy of the complete report, methodology, gene list, and version date.

For an overview of consumer-directed ordering and follow-up, see direct-access lab testing.

Privacy, consent, and family implications

Genomic information can be identifying, long-lived, and relevant to biological relatives. Consent should cover more than specimen collection.

Questions to review before ordering

• Who performs the analysis, and which privacy policy and terms apply?
• Will the sample or data be retained, deidentified, used for research, or shared with third parties?
• Can you opt out of secondary use and request sample destruction or account deletion?
• Will raw data be available, and what security responsibilities come with downloading it?
• Could the result reveal unexpected biological relationships or information relevant to relatives?
• What are the limits of federal and state genetic-discrimination protections?

GINA provides important federal protections in health insurance and employment, but it does not cover every setting. In particular, federal GINA protections do not extend to life, disability, or long-term-care insurance. State laws vary. Consider these issues before testing, not only after a high-impact result appears.

If the result may affect relatives, plan how to share the original report accurately and respectfully. A genetic counselor can help distinguish who may benefit from targeted family testing and who is unlikely to gain useful information.

Special testing situations

Hereditary cancer risk

Inherited-cancer evaluation is different from tumor profiling. Tumor analysis examines changes in cancer cells and can sometimes suggest a germline finding, but it does not replace a dedicated inherited-risk evaluation. Strong personal or family patterns, early-onset disease, multiple related cancers, or a known familial variant warrant professional risk assessment. A limited founder-variant screen should not be substituted for a comprehensive evaluation when the history points to a broader question. For the role and limits of non-genetic markers, see cancer blood tests and tumor markers.

Cardiovascular and clotting risk

Inherited findings are one layer of cardiovascular risk. Blood pressure, tobacco exposure, diabetes, lipids, kidney function, pregnancy, medications, age, and family history may be equally or more important for current decisions. Inherited-thrombophilia analysis is not a screening bundle for everyone and does not diagnose an active clot. For broader context, see heart health blood tests.

Brain and neurologic questions

Many neurologic conditions have genetic and non-genetic causes. Predictive testing for an adult-onset condition can have psychological, family, employment, and insurance implications even when prevention or treatment options are limited. Pretest counseling is especially valuable. Current biomarkers may address different causes of symptoms; review brain and neurological blood tests for that separate layer of evaluation.

Reproductive carrier screening and pregnancy

Carrier screening should be timed so that results, partner testing, residual risk, and reproductive options can be discussed without unnecessary delay. A negative carrier result reduces risk only for the conditions and variants adequately covered. Prenatal screening is not the same as diagnostic testing. For non-genetic laboratory context, see pregnancy blood tests and prenatal screening.

Children and adolescents

Testing a child is most appropriate when the result may clarify a current health problem or change care during childhood. Predictive testing for adult-onset conditions without childhood management implications raises consent and autonomy concerns and generally deserves genetics-specialist review.

Ancestry, equity, and polygenic scores

Variant databases and risk models have not represented all populations equally. A score developed primarily in one ancestry group may perform differently in another. Ask how the model was validated, whether absolute risk was calibrated for the relevant population, and whether non-genetic risk factors are included.

Epigenetic age and longevity reports

Epigenetic markers can change with age and exposures and are scientifically important, but a consumer epigenetic-age estimate is not a diagnosis or a validated prescription for treatment. Different algorithms can produce different estimates, and evidence that changing a score improves health outcomes remains limited. Keep these reports separate from established clinical evaluation. For current biomarker context, see healthy aging and longevity blood tests.

What to do next

Before testing

1. Write the health question and the decision the result could change.
2. Gather personal records, a three-generation family history, and any relative's original genetic report.
3. Compare method, genes, regions, variant types, exclusions, confirmation policy, and report examples.
4. Review consent, privacy, research, retention, and deletion terms.
5. Arrange a genetics professional or prescriber review when the result could alter surveillance, surgery, reproductive plans, or medication.

After testing

1. Read the full report, including limitations and methodology.
2. Confirm high-impact findings when the report or clinical context requires it.
3. Do not act on a variant of uncertain significance as though it were pathogenic.
4. Discuss implications for relatives without assuming that they have the same result.
5. Ask whether reclassification updates are automatic and when reanalysis may be reasonable.
6. Keep the original report and versioned gene list in a secure place.

Fictional walkthrough: choosing scope before ordering

Jordan, a fictional 38-year-old, learns that an aunt had early-onset breast cancer but cannot obtain the aunt's genetic report. Jordan first builds a family history and meets with a genetics professional. Because no familial variant is documented, a narrow founder-variant product might miss relevant causes. The professional selects an appropriate clinical strategy based on the complete history. When the report returns negative, Jordan does not interpret it as zero cancer risk; screening recommendations are still based on personal and family factors. This example shows why the clinical question and test scope come before the product name.

When not to order yet

• You cannot identify the question the result should answer.
• You would make an irreversible medical decision without confirmation or professional interpretation.
• A more informative affected relative is available for testing first.
• The product does not disclose its genes, methods, limitations, or laboratory.
• You have not reviewed privacy terms or considered insurance implications.
• You are seeking emergency diagnosis or treatment.

When to seek urgent care

Genetic testing is not an emergency service. Call emergency services or seek urgent medical care for symptoms such as chest pain, severe shortness of breath, signs of stroke, a suspected blood clot, severe allergic reaction, suicidal thoughts, pregnancy emergencies, or other rapidly worsening symptoms. Do not wait for a genetic or routine laboratory result.

Questions to bring to a clinician, pharmacist, or genetic counselor

• What exact question will this test answer, and is this the correct person in the family to test first?
• Does the method cover the variant types that matter for this condition?
• How would positive, negative, and uncertain results change care?
• Will an important result need confirmation in a second specimen?
• Could this result affect medication, screening, pregnancy, or relatives?
• What does my result mean for absolute risk, not only relative risk?
• How and when will the laboratory update a reclassified variant?

You can search the National Society of Genetic Counselors directory for a genetics professional. Availability and licensure vary by location.

Frequently asked questions

Is genetic testing the same as genomic testing?

No. Genetic testing often focuses on a gene, variant, chromosome, or panel. Genomic testing generally covers a broader portion of DNA. Product marketing does not always use the terms consistently, so inspect the actual scope and method.

Does a positive genetic result mean I will develop the condition?

Not always. Some findings are highly penetrant, while others change risk modestly. Age, sex, environment, other genes, and medical history can influence whether and how a condition appears.

Does a negative result mean I have no inherited risk?

No. It means no reportable finding was identified within that test's scope. Unanalyzed genes, uncovered variant types, scientific knowledge gaps, and non-genetic factors may still matter.

What is a variant of uncertain significance?

It is a DNA change for which current evidence is insufficient or conflicting. It should not be treated as a pathogenic finding, and family or clinical management should not be changed on that result alone.

Should I choose the largest available panel?

Not automatically. A broader panel can improve coverage when several genes fit, but it also increases uncertain and secondary findings. The narrowest adequate scope is often the most interpretable.

Can raw consumer DNA data diagnose a disease?

No. Raw data can contain technical errors and usually lacks complete clinical interpretation. Confirm a medically important finding through an appropriate clinical laboratory and qualified professional before acting.

Can pharmacogenomics tell me which medicine will work?

It can inform some gene-drug relationships, but it cannot account for every factor affecting response. Diagnosis, other medicines, kidney and liver function, age, pregnancy, adherence, and clinical monitoring still matter.

Should I change medication after receiving a pharmacogenomic result?

No medication change should be made from a report alone. Share the complete result with the prescriber or pharmacist, who can evaluate the applicable label or guideline and your full clinical context.

Can an inherited-risk result change over time?

Your germline DNA generally does not change, but the scientific interpretation can. A variant may be reclassified, a gene-disease relationship may strengthen or weaken, and management guidance may be updated.

Will genetic testing affect my relatives?

It may provide information relevant to biological relatives, but it does not prove that they carry the same variant. Share the original report and encourage individualized counseling rather than assuming their result.

Are genetic-testing data protected by GINA?

GINA provides federal protections in employment and health insurance, with exceptions, but it does not cover life, disability, or long-term-care insurance. Other laws and state protections vary.

Do I need genetic counseling?

Counseling is particularly valuable for high-impact hereditary risk, pediatric or prenatal decisions, neurologic predictive testing, broad sequencing, unexpected family relationships, uncertain findings, and results that may change treatment or surgery.

How often should genetic testing be repeated?

Germline testing is not usually repeated like a fluctuating biomarker. Repeat or expanded analysis may be reasonable if the original method was limited, a new clinical question arises, or knowledge and technology have changed. Reanalysis of existing data may sometimes be more appropriate than recollection.

How can Ulta Lab Tests help?

Ulta Lab Tests provides online category and product pages where available options, specimens, and preparation instructions can be reviewed. Because catalogs and requirements change, verify the exact page at the time of ordering and involve a qualified professional when the decision is high impact.

Use DNA information as one layer of evidence

Genetic and genomic testing is most useful when it begins with a precise question and ends with a responsible interpretation plan. Match the method to the question, distinguish inherited susceptibility from current physiology, confirm high-impact findings when needed, and protect privacy before sharing data. A larger report is not necessarily a better answer. The goal is reliable information that can be integrated with medical history, family history, current laboratory context, and qualified guidance.

References and further reading

1. MedlinePlus Genetics: What are the different types of genetic tests?
2. MedlinePlus Genetics: What do the results of genetic tests mean?
3. MedlinePlus Genetics: How can consumers be sure a genetic test is valid and useful?
4. MedlinePlus Genetics: What are the risks and limitations of genetic testing?
5. MedlinePlus Genetics: What are secondary findings from genetic testing?
6. National Cancer Institute: Genetic Testing for Inherited Cancer Risk
7. U.S. Food and Drug Administration: Direct-to-Consumer Tests
8. U.S. Food and Drug Administration: Table of Pharmacogenetic Associations
9. U.S. Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug Labeling
10. Centers for Disease Control and Prevention: Pharmacogenomics
11. Clinical Pharmacogenetics Implementation Consortium: Guidelines
12. National Human Genome Research Institute: Genetic Discrimination
13. Centers for Disease Control and Prevention: Epigenetics, Health, and Disease
14. Centers for Medicare & Medicaid Services: Clinical Laboratory Improvement Amendments
15. American College of Medical Genetics and Genomics and Association for Molecular Pathology: Standards and guidelines for sequence-variant interpretation
16. American College of Medical Genetics and Genomics: Screening for autosomal recessive and X-linked conditions during pregnancy and preconception
17. American College of Medical Genetics and Genomics: Clinical application of polygenic risk scores
18. American College of Medical Genetics and Genomics: Practice Guidelines and current resources

Editorial Disclosure, Authorship, and Medical Note

Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.

Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026

Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.